July 24, 2008
ACT Partners With KBP and University of Louisville in HPV Vaccine Program
Advanced Cancer Therapeutics has signed two new collaborative agreements to advance development of the company's novel human papillomavirus vaccine program.
The first agreement with the University of Louisville's James Graham Brown Cancer Center grants Advanced Cancer Therapeutics (ACT) exclusive worldwide development and commercialization rights to monovalent vaccines derived from the minor capsid protein (L2) of human papillomavirus (HPV).
The second agreement with Kentucky BioProcessing (KBP), of Owensboro, Kentucky, is for exclusive worldwide development and commercialization rights to KBP's Geneware plant based gene expression system for development of an HPV vaccine.
Hugh Haydon, chairman of KBP, said: "Joining together on this exciting project allows ACT, KBP and the Brown Cancer Center to leverage the business, scientific and intellectual property capabilities of three Kentucky based entities to develop a solution to a very serious world health concern. KBP is proud to be a part of this collaboration."